Inhalon Biopharma is a clinical-stage biotechnology company developing revolutionary inhaled antibody treatments for acute respiratory infections (ARIs). The company's unique science is based on its proprietary muco-trapping antibody platform, which targets and binds viruses and bacteria in mucus, the protective lining of the airways. This innovative approach enables direct and localized treatment of respiratory infections, potentially preventing the spread of pathogens and reducing the severity of symptoms.

Inhalon Biopharma

Founded: 2018
Location: Morrisville, NC
Employee range: 1 - 10
Clinical stage: Clin1
Therapy area: COVID-19
Drug types: INF
Lead product: IN-006
Funding: 10-100M

Drug notes:

About:

Jobs: